Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00676338 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 820
- Enrollment target
NCT00676338 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 820 participants.
The verdict
NCT00676338, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 820 participants
- Enrollment target
Study Summary
This study will compare the effects of 2.0 mg exenatide once weekly injection as monotherapy to 3 active comparators(metformin, dipeptidyl peptidase-4 inhibitor, and thiazolidinedione) in drug naive patients with type 2 diabetes treated with diet and exercise.
Interventions
- DRUG metformin
- DRUG pioglitazone
- DRUG sitagliptin
- DRUG exenatide once weekly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 820 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00676338
The ClinicalTrials.gov registry entry for NCT00676338 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 820 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which metformin is the first listed.
NCT00676338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00676338 about?
NCT00676338 is a clinical study titled "Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)". This study will compare the effects of 2.0 mg exenatide once weekly injection as monotherapy to 3 active comparators(metformin, dipeptidyl peptidase-4 inhibitor, and thiazolidinedione) in drug naive patients with type 2 diabetes treated with diet and exercise.
What is the current status of trial NCT00676338?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 820 participants. The study started on 2008-11. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00676338?
The interventions under investigation include: metformin (DRUG), pioglitazone (DRUG), sitagliptin (DRUG), exenatide once weekly (DRUG).
Who is sponsoring clinical trial NCT00676338?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.